homologous – Page 14 – Communicable Diseases Research

Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination

동종 Spikevax 또는 이종 Vaxzevria-Spikevax 백신 접종 후 SARS-CoV-2 Delta 변이체에 대한 중화 항체의 강력한 유도

Article

Published on 2022-02-012022-09-11
Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience

심장 이식 환자에게 BNT162b2 백신 3차 접종: 면역원성과 임상 경험

Article

Published on 2022-02-012022-09-12
Journal: The Journal of heart and lung transplantation : th [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] adverse events anti-RBD Anti-RBD antibody BNT162b2 BNT162b2 vaccine booster booster dose C-reactive protein cellular immune responses clinical experience Cohort COVID-19 COVID-19 pandemic defined domain dose elicited Heart transplantation homologous humoral IgG IgG anti-RBD immune response Immunocompromised immunogenicity increase in injection investigated likelihood majority Mild mycophenolate Neutralizing antibodies neutralizing antibody neutralizing capacity Pain Patient patients Pfizer populations positive antibody response primary doses RBD recipients reduced rejection repeated safety profile SARS-CoV-2 neutralization second dose Serious Adverse Event Specific T-cell response subset T cell response the vaccine Tolerability vaccine response vaccine-induced antibody response were assessed were recorded
[DOI] 10.1016/j.healun.2021.08.010 PMC 바로가기 [Article Type] Article

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint

임상 종말점에 의한 SARS-COV-2 델타 변이체에 대한 백신 유발 중화 항체 및 시변 백신-특이 적 효능의 장기 동역학 예측

Research Article

Published on 2022-01-282022-09-01
Journal: BMC Medicine [Category] SARS, 변종, 진단,

[키워드] 95% CI administration age antibody BNT162b2 caused Clinical severity CoronaVac COVID-19 pandemic COVID-19 vaccines decrease delta variant dose doses Efficacy Endpoint evaluate FIVE homologous Inactivated Vaccines Infection marker mRNA mRNA vaccine mRNA vaccines mRNA-1273 neutralization neutralization titer neutralizing antibody NVX-CoV2373 predict predicted prediction Prevent Protein responses Result SARS-CoV-2 SARS-CoV-2 Delta variants second dose severe COVID-19 supplementary material Surveillance symptomatic the SARS-CoV-2 Time-varying efficacy titers vaccination Vaccine variants
[DOI] 10.1186/s12916-022-02249-9 PMC 바로가기 [Article Type] Research Article

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial

Research

Published on 2022-01-272022-10-05
Journal: Nature Medicine [Category] COVID19(2023년), SARS, 임상,

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients A multicenter prospective observational study

혈액 투석 환자에서 동종 BNT/BNT 및 ChAd/ChAd SARS-CoV-2 백신 접종과 비교한 이종 ChAd/BNT의 체액 면역원성 및 내약성 다기관 전향적 관찰 연구

Observational Study

Published on 2022-01-272022-09-10
Journal: Journal of Nephrology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법,

[키워드] Abstract Adverse reaction Adverse reactions antibody appear AstraZeneca BNT BNT162b2 BNT162b2 vaccine ChAd ChAdOx1 ChAdOx1-nCoV-19 COVID-19 dose first dose first vaccination Hemodialysis Heterologous homologous Humoral immunity humoral immunogenicity IgG antibody IgG level IgG levels induce kidney limitation median mRNA-/vectored vaccines multicenter multivariable Multivariable regression analysis nCoV nucleocapsid observational study Patient patients percentile prospective observational study regression analysis Result SARS-CoV-2 SARS-CoV-2 spike IgG SARS-CoV-2 vaccination second dose severe adverse reactions Side effect Side effects significantly higher Tolerability vaccination Vaccine were assessed
[DOI] 10.1007/s40620-022-01247-7 PMC 바로가기 [Article Type] Observational Study

Homologous and Heterologous Covid-19 Booster Vaccinations

Original Article

Published on 2022-01-262022-11-01
Journal: The New England Journal of Medicine [Category] COVID-19, Fulltext, SARS,

[키워드] acute respiratory syndrome Ad26.COV2.S Ad26.COV2.S vaccine antibody assigned binding BNT162b2 booster Booster vaccine Breakthrough infection CD8+ T cell CD8+ T-cell clinical trial combinations conducted coronavirus coronavirus disease dose effective Emergency use authorization enrolled had no headache Heterologous homologous humoral immunogenicity immunogenic Infection injection Injection-site pain malaise Moderna mRNA vaccine mRNA-1273 myalgia Neutralizing antibody titer Neutralizing titer Open-label participant Pfizer–BioNTech primary end point pseudovirus reactogenicity receive recipient recipients regimen reported Result safety profile SARS-CoV-2 SARS-CoV-2 D614G T-cell Response the United State The United States Trial Vaccine virus particles
[DOI] 10.1056/NEJMoa2116414 PMC 바로가기 [Article Type] Original Article

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

오미크론 변이체는 부스트 후 백신에 의해 유도된 면역 혈청에 대해 다른 SARS-CoV-2 변이체보다 낮은 중화 민감도를 나타냈습니다.

Coronaviruses

Published on 2022-01-242022-09-10
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] B.1.1.529 BBIBP-CorV Beta boost booster booster vaccination COVID-19 Delta dose elicited escaped GMT GMTs Heterologous heterologous protein homologous homologous or heterologous immune Immune escape immune protection immunogenicity IMPROVE inactivated Inactivated vaccine Inactivated Vaccines limit multiple mutations neutralization neutralization ability neutralization activity Neutralizing neutralizing antibody omicron patients positive protein subunit vaccine prototype pseudotype Pseudotyped viruses quantitation raised reduction reported SARS-CoV-2 SARS-CoV-2 variant sensitivity sera significantly increased Subunit vaccine titre Vaccine variant VoC VOCs ZF2001
[DOI] 10.1080/22221751.2021.2022440 PMC 바로가기 [Article Type] Coronaviruses

Humoral immune response after different SARS-CoV-2 vaccination regimens

상이한 SARS-COV-2 백신 접종 요법 후 체액 면역 반응

Research Article

Published on 2022-01-212022-09-01
Journal: BMC Medicine [Category] SARS, 변종, 진단, 치료기술,

[키워드] age Alpha anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antibody Response Antigen AstraZeneca avidity AZD1222 B.1.1.7 B.1.1.7 variant B.1.617.2 binding BNT162b2 boost booster vaccination ChAdOx1 ChAdOx1 nCoV-19 comparable Concentration correlation COVID-19 cVNT delta variant examined first vaccination followed by Heterologous homologous humoral immune response Humoral immunity IgG IgG antibodies IgG antibody immune response immunoblot Immunoglobulin Immunoglobulin G individual investigation leads Maturity process Moderna mRNA mRNA vaccine neutralisation test Neutralising Antibodies Occurrence Pfizer/BioNTech Prevalence RBD Receptor binding domain recipient reduction in regimen Result robust S-protein SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 vaccination sera Seroconversion significantly higher significantly lower strength subunit supplementary material sVNT tested the antibody response the RBD the SARS-CoV-2 the vaccine titre titres trimeric vaccination Vaccination schemes Vaccine vaccine dose vaccinee variant Virus neutralisation Virus variants of concern VoC was done was measured was used were measured
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2

Immunology

Published on 2022-01-192022-11-01
Journal: Frontiers in Immunology [Category] COVID-19,

[키워드] Against amplitude Antibody Response B-cell response BNT162b2 Cell ChAdOx1 nCoV-19 change collected detect detectable driven by early response examined first dose Frame Heterologous heterologous vaccination regimen homologous IgA IgA response IgA responses IgG IgG response immune response immunogenic increase increases in Kinetics latency marker mRNA-1273 mRNA-based vaccine neutralization Neutralization assay no difference participant performed plasma populations regimen regimens response responses Result SARS-CoV-2 second dose second vaccination serum sample Seven shown the antibody response vaccination while
[DOI] 10.3389/fimmu.2022.811020 PMC 바로가기 [Article Type] Immunology

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants

Article

Published on 2022-01-032022-10-28
Journal: Vaccines [Category] COVID-19,

[키워드] 95% CI adverse event blood sample BNT162b2 collected comparable CoronaVac COVID-19 D614G declined Delta variants dose Effectiveness evaluated geometric mean titre GMT group groups heterologous vaccination heterologous vaccine homologous immunogenicity Live virus microneutralization mRNA naïve Neutralization antibody Neutralizing activity neutralizing antibody participant recruited reduced Safe SARS-CoV-2 SARS-CoV-2 variant severe adverse events Strategy the antibody response the mean the SARS-CoV-2 the vaccine Vaccination strategy Vaccine vaccine immunogenicity Vaccines variant variants virus waned wild-type
[DOI] 10.3390/vaccines10010072 PMC 바로가기 [Article Type] Article